慢性髓性白血病:综述
本文综述慢性髓性白血病的流行病学、诊断标准、分期与治疗。美国年发病约9300例,约90%患者为慢性期(原始细胞<10%、无髓外白血病、嗜碱性粒细胞<20%、血小板100–1000×10⁹/L)。自2000年以来,第一代(伊马替尼)与第二代(博舒替尼、达沙替尼、尼洛替尼)酪氨酸激酶抑制剂使CML相关年死亡率从10%–20%降至1%–2%,生存率与同龄一般人群相似。第二代和第三代TKI使更多患者快速达到并维持BCR::ABL1清除,但各药不良反应不同,选药时需权衡,并帮助患者最大化依从性。
要点
- 慢性期CML定义为血液或骨髓原始细胞<10%、无髓外白血病证据、嗜碱性粒细胞<20%、血小板100–1000×10⁹/L,约90%患者以此期起病。
- 自2000年以来TKI使CML相关年死亡率从10%–20%降至1%–2%,患者生存率与同龄一般人群相似。
- 美国FDA已批准6种BCR::ABL1 TKI,其中5种用于一线(伊马替尼、达沙替尼、博舒替尼、尼洛替尼、阿西米尼),5种用于初始治疗后疾病进展(达沙替尼、博舒替尼、尼洛替尼、帕纳替尼、阿西米尼)。
- 所有TKI均有血液学毒性如骨髓抑制,药物特异性不良反应包括达沙替尼致胸腔积液、尼洛替尼和帕纳替尼致动脉闭塞事件(心肌梗死、卒中、外周动脉疾病)、博舒替尼致胃肠道紊乱、帕纳替尼/阿西米尼/尼洛替尼致淀粉酶和脂肪酶升高伴胰腺炎,选药时应考虑这些不良反应。
- 异基因造血干细胞移植治愈率20%–60%(取决于移植时CML分期),保留用于对第二代TKI无反应、对多种TKI不耐受或加速期/急变期患者。
适用人群与场景
- 美国每年新诊断约9300例CML,美国约15万人、全球约500万人患病。
- 约90%的CML患者起病时为慢性期;约1%–2%的患者起病时即为急变期。
诊断标准与关键阈值
- 慢性期CML:血液或骨髓原始细胞<10%、无髓外白血病证据、嗜碱性粒细胞<20%、血小板计数100–1000×10⁹/L。
- 急变期CML(CML-BP):世界卫生组织定义为原始细胞/未成熟细胞≥20%;MD安德森癌症中心和欧洲白血病网定义为≥30%。
处置流程与药物剂量
- 自2000年以来,第一代BCR::ABL1 TKI(如伊马替尼)和第二代TKI(如博舒替尼、达沙替尼、尼洛替尼)使CML相关年死亡率从10%–20%降至1%–2%,患者生存率与同龄一般人群相似。
- 美国FDA已批准6种BCR::ABL1 TKI:5种用于一线治疗(伊马替尼、达沙替尼、博舒替尼、尼洛替尼、阿西米尼),5种用于初始治疗后疾病进展(达沙替尼、博舒替尼、尼洛替尼、帕纳替尼、阿西米尼)。
- 所有TKI改善生存的效应相似,但第二代和第三代TKI使更多患者能快速达到并维持BCR::ABL1清除。
- 维持治疗反应性需重视用药依从性。
- 所有TKI均与血液学毒性(如骨髓抑制)相关,并有药物特异性不良反应:达沙替尼致胸腔积液;尼洛替尼、帕纳替尼致动脉闭塞事件(心肌梗死、卒中、外周动脉疾病);博舒替尼致胃肠道紊乱;帕纳替尼、阿西米尼、尼洛替尼致淀粉酶和脂肪酶升高伴胰腺炎;选择TKI时应考虑这些不良反应。
- 异基因造血干细胞移植是合理安全的治疗,治愈率20%–60%(取决于移植时CML分期);保留用于对第二代TKI无反应、对多种TKI不耐受、或加速期CML/急变期CML患者。
研究设计与关键结果
- 本综述描述CML为BCR::ABL1融合基因定义的骨髓增殖性肿瘤,约90%患者为慢性期,约1%–2%起病即为急变期。
- 自2000年以来TKI使CML相关年死亡率从10%–20%降至1%–2%,患者生存率与同龄一般人群相似。
- 美国FDA已批准6种BCR::ABL1 TKI,其中5种用于一线,5种用于初始治疗后疾病进展;所有TKI改善生存的效应相似,但第二代和第三代TKI使更多患者快速达到并维持BCR::ABL1清除。
- 药物特异性不良反应包括达沙替尼致胸腔积液,尼洛替尼和帕纳替尼致动脉闭塞事件,博舒替尼致胃肠道紊乱,帕纳替尼、阿西米尼、尼洛替尼致淀粉酶和脂肪酶升高伴胰腺炎。
- 异基因造血干细胞移植治愈率20%–60%,保留用于对第二代TKI无反应、对多种TKI不耐受、或加速期/急变期患者。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- CML通常可经TKI有效治疗,生存率改善至与同龄一般人群相似;许多患者需要持续TKI治疗。
- 选择TKI治疗时应考虑不良反应,并帮助患者最大化对TKI治疗的依从性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Chronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.
OBSERVATIONS: Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, which is defined by the BCR::ABL1 oncogene that develops after fusion of the ABL1 proto-oncogene to the constitutively active BCR gene. Approximately 90% of people with CML present with an indolent chronic phase of CML, defined as blasts of less than 10% in the blood or bone marrow, absence of extramedullary evidence of leukemia, basophils of less than 20%, and platelet counts of 100 to 1000 × 109/L. The most advanced stage is CML blastic phase (CML-BP), characterized by the World Health Organization as 20% or more blasts/immature cells and by the MD Anderson Cancer Center and European LeukemiaNet as 30% or more. Approximately 1% to 2% of patients with CML present with CML-BP. Since 2000, first-generation tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1, such as imatinib, and second-generation TKIs, such as bosutinib, dasatinib, and nilotinib, have improved CML-related mortality from 10% to 20% per year to 1% to 2% per year, such that patients with CML have survival rates similar to those of a general age-matched population. Six BCR::ABL1 TKIs have been approved by the US Food and Drug Administration, including 5 that are first-line treatment (imatinib, dasatinib, bosutinib, nilotinib, and asciminib) and 5 approved for treatment after disease progression despite initial therapy (dasatinib, bosutinib, nilotinib, ponatinib, asciminib). Effects on improved survival are similar with all TKIs, although more patients are able to promptly achieve and maintain BCR::ABL1 clearance with second- and third-generation TKIs. Medication adherence is important to maintain treatment responsiveness. All TKIs are associated with hematologic toxicity, such as myelosuppression, with additional agent-specific adverse effects, such as pleural effusion (dasatinib), arterio-occlusive events such as myocardial infarction, stroke, and peripheral artery disease (nilotinib, ponatinib), gastrointestinal disturbance (bosutinib), or increased amylase and lipase with pancreatitis (ponatinib, asciminib, nilotinib). These adverse effects should be considered when selecting a TKI. Allogeneic hematopoietic stem cell transplant is a reasonably safe therapy, with cure rates ranging from 20% to 60% based on the stage of CML at the time of transplant. Stem cell transplant is reserved for patients with CML who do not respond to second-generation TKIs, those with intolerance to multiple TKIs, or those with accelerated-phase CML or CML-BP.
CONCLUSIONS AND RELEVANCE: Chronic myeloid leukemia is a myeloproliferative neoplasm that can typically be effectively treated with TKIs, improving survival similar to that of a general age-matched population. Many patients require continuous TKI therapy. Therefore, TKI therapy should be selected with consideration of adverse effects, and patients should be helped to maximize adherence to TKI treatment.
参考来源
- Jabbour E, Kantarjian H. Chronic Myeloid Leukemia: A Review. JAMA. 2025. PMID: 40094679. doi:10.1001/jama.2025.0220
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。